Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13.Read More
Stereotaxis (NASDAQ:STXS) announced a senior management change in a move designed to help re-establish the company’s growth trajectory.Read More
Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN).Read More
Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.Read More
Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.
Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.Read More
Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million.
The offering was completed through a syndicate of underwriters led by GMP Securities, and included Echelon Wealth Partners and Mackie Research Capital.Read More
Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4-million.
The company has agreed to grant underwriters an overallotment option to purchase up to an additional 2,373,000 common shares at the same price for 30 days following closing. The offering is expected to close on Nov. 14, subject to regulatory approvals.Read More
Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system.
TULSA-PRO, which received CE Mark approval in April 2016, combines real-time MRI with transurethral, robotically driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate, while simultaneously protecting critical surrounding anatomy from potential side effects.Read More
Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.
The transactions include an equity financing of $24-million, satisfaction in full of outstanding debt to Healthcare Royalty Partners for a payment of $13-million, and the addition to the board of three new directors with significant operational and financial experience in the medical device industry.Read More
The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN.
TACT is a prospective, single-arm pivotal clinical study of 110 patients aimed at further evaluating the safety and efficacy of TULSA-PRO to ablate prostate tissue in patients with localized, organ-confined prostate cancer. Multiple sites in the U.S., Germany, Netherlands, Spain and Canada will participate in the trial.Read More
Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO. Steven Plymale, the company’s current CEO, will transition to President and COO.
Dr. Menawat has been a member of Profound’s board since October 2014. Most recently, he was president and CEO of Novadaq Technologies, which pioneered the field of fluorescence imaging in the operating room.Read More
Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday.Read More
Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer.
TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing a highly precise prostate treatment tailored to patient-specific anatomy.Read More
Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue.
Under the accord, the two companies will collaborate in the commercialization of TULSA-PRO in Europe followed by Canada, the U.S. and other markets, subject to regulatory clearance in those jurisdictions.Read More
Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain.
Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology.Read More
GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday.
The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side effects.Read More
Profound Medical (TSX-V:PRN) has received CE Mark approval for the commercial sale of Tulsa-Pro.
Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically-driven ultrasound and closed-loop thermal feedback control to provide a highly precise treatment tailored to patient-specific anatomy and pathology.Read More